DM's higher sensitivity at detecting breast cancer raised concerns that its introduction into screening programs would increase the diagnosis of clinically unimportant cancers — cancers that, if left undetected and therefore untreated, would never have surfaced clinically in the person's lifetime.
Data analysis showed an increased incidence of ductal carcinoma in situ (DCIS), a precursor for invasive breast cancer, in the years after the introduction of population-based screening with DM. The development of low-grade DCIS can extend over more than three decades; however, high-grade DCIS is associated with far more rapid cancer invasion.
"More DCIS and invasive cancers are detected with the use of DM in breast cancer screening compared to SFM," said Doctor Adriana M.J. Bluekens from the National Expert and Training Centre for Breast Cancer Screening in Nijmegen and St. Elisabeth Hospital in Tilburg, both in the Netherlands. "In the mix of low- to high-grade DCIS lesions, there is no shift to the detection of low-grade lesions in digital screening. Instead of this, we noticed a larger amount of high-grade lesions, which are regarded as precursors of high-grade invasive tumors."
To learn more about the impact of DM on screening programs, Dutch researchers compared it with SFM in screening mammograms performed between 2003 and 2007. Recall was indicated in 18,896 cases out of almost two million mammograms studied, and 6,410 women were diagnosed with breast cancer. As expected, DM had a higher initial sensitivity for detecting cancer, with a detection rate per thousand of 6.8, compared with 5.6 for SFM.
Detection of high-grade DCIS with DM was 58.5 percent, compared with 50.5 percent for SFM. "This gain is largely due to enhanced depiction of microcalcifications with DM resulting in improved detection of DCIS and invasive carcinoma with an intraductal component," Bluekens said.
The initial recall rate was higher with DM: 4.4 percent, compared with 2.6 percent for SFM. However, the transition to digital mammography did not result in a disproportionate increase in low-grade DCIS lesions, which are linked to possible overdiagnosis.
"The follow-up period of the different digital screening programs is not sufficiently long enough to analyze mortality effect separately from that of SFM," Bluekens said. "However, surrogate parameters, such as stage distribution and tumor characteristics of DM-detected cancers, do indicate the continuation of mortality decrease with the transformation of SFM to DM in screening programs."
COMPAMED.de; Source: Radiological Society of North America